Skip to content

Rotigotine

    Brands

    DEA Class;  Rx

    Common Brand Names; Neupro

    • Antiparkinson Agents, Dopamine Agonists

    Non-ergoline dopamine agonist; transdermal patch formulation
    Used for early and advanced Parkinson’s disease and restless legs syndrome
    May cause abrupt onset of sleep or excessive drowsiness resulting in serious harm

    Indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease.

    For the treatment of Restless Legs Syndrome (RLS).
     
     

    Hypersensitivity

    • Nausea (34-48%)
    • Application site reactions (including erythema, pruritus, irritation, burning, dermatitis, inflammation, papulae, vesicle, pain) (21-46%)
    • Dizziness (14-22%)
    • Somnolence (12-20%)
    • Vomiting (10-20%)
    • Fatigue (6-18%)
    • Insomnia (5-11%)
    • Hyperhidrosis (3-11%)
    • Application site reactions (36-46%)
    • Somnolence (32%)
    • Nausea (22-28%)
    • Dizziness (14-23%)
    • Dyskinesia (14-17%)
    • Edema peripheral (9-14%)
    • Insomnia (9-14%)
    • Hallucinations (7-14%)
    • Arthralgia (8-11%)
    • Application site reactions (23-43%)
    • Nausea (15-23%)
    • Headache (15-21%)
    • Asthenia (7-14%)

    Patients with Parkinson disease or RLS may experience new or worsening mental status and behavioral changes; these may include sudden onset of sleep while engaging in activities of daily living, consider dose reduction or discontinuation of treatment if patient develops compulsive behavior

    There are no adequate data on developmental risk associated with use in pregnant women

    There are no data on presence of drug in human milk, effects on the breastfed infant, or on milk production; however, inhibition of lactation may occur because drug decreases secretion of prolactin in humans; studies have shown that rotigotine and/or its metabolite(s) are excreted in rat milk

    Adults

    8 mg/24 hours transdermally for PD; 3 mg/24 hr transdermally for RLS.

    Geriatric

    8 mg/24 hours transdermally for PD; 3 mg/24 hr transdermally for RLS.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Rotigotine

    transdermal patch

    • 1mg/24 hr
    • 2mg/24 hr
    • 3mg/24 hr
    • 4mg/24 hr
    • 6mg/24 hr
    • 8mg/24 hr